BioRestorative Reports Promising Phase 2 Trial Results

BioRestorative Therapies ( (BRTX) ) has provided an announcement.

On June 13, 2025, BioRestorative Therapies presented promising preliminary data from its Phase 2 clinical trial of BRTX-100, an autologous stem cell therapy for chronic lumbar disc disease, at the ISSCR 2025 Annual Meeting. The data showed significant improvements in pain and function among subjects, with over 74% achieving more than 50% improvement in function and over 72% reporting similar reductions in pain. The trial’s progress, with an increase in evaluated subjects from 15 to 36, marks an important step toward full enrollment and potential FDA approval, underscoring the therapy’s potential to address a significant unmet need in chronic lower back pain treatment.

The most recent analyst rating on (BRTX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on BioRestorative Therapies stock, see the BRTX Stock Forecast page.

Spark’s Take on BRTX Stock

According to Spark, TipRanks’ AI Analyst, BRTX is a Neutral.

BioRestorative Therapies faces significant financial challenges with ongoing net losses and negative cash flow, affecting its stock performance. However, recent improvements in financial metrics, substantial revenue growth, and promising clinical developments provide some optimism. Technical indicators suggest a neutral market position. Although valuation remains a concern due to the lack of profitability, the company’s strategic focus on clinical trials and research offers potential for future growth.

To see Spark’s full report on BRTX stock, click here.

More about BioRestorative Therapies

BioRestorative Therapies, Inc. is a clinical-stage regenerative medicine company focused on developing stem cell-based therapies for serious musculoskeletal conditions. The company operates two core clinical development programs targeting disc/spine disease and metabolic disorders, and also runs a commercial BioCosmeceutical platform.

Average Trading Volume: 84,390

Technical Sentiment Signal: Hold

Current Market Cap: $14.11M

See more data about BRTX stock on TipRanks’ Stock Analysis page.